New targeted therapies and other advances in the management of anaplastic thyroid cancer

Current Opinion in Oncology

Volumn 25, Issue 1, 2013, Pages 44-49

  Deshpande, Hari A ^a   Roman, Sanziana ^b   Sosa, Julie A ^b  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anaplastic thyroid cancer; Combretastatin; Pazopanib

Indexed keywords

B RAF KINASE; CARBOPLATIN; CASPASE 3; COMBRETASTATIN A4 PHOSPHATE; DOCETAXEL; DOXORUBICIN; IMATINIB; PACLITAXEL; PAZOPANIB; SORAFENIB;

ALOPECIA; ANAPLASTIC THYROID CANCER; APOPTOSIS; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DESQUAMATION; DIFFERENTIATED THYROID CANCER; DYSPNEA; EDEMA; FATIGUE; GENE MUTATION; HUMAN; HYPONATREMIA; LYMPHOCYTOPENIA; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA HALF LIFE; PRIORITY JOURNAL; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; THORAX PAIN; TREATMENT RESPONSE; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIBENZYLS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; THYROID NEOPLASMS;

EID: 84871971926     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32835a448c     Document Type: Review

References (38)

1. Udelsman R, Carling T. Chapter 108. Thyroid Tumors. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. In: Devita VT, Lawrence TS, Rosenberg SA, editors. 2011 Lippincott Williams and Wilkins: Philadelphia. pp. 1457-1472
2. Sloan LW. On theorigin, characteristics and behavior of thyroid carcinoma. J Clin Endocrinol Metab 1954; 14:1309-1335
3. Smith LW. Certain so-called sarcomas of the thyroid. Arch Pathol 1930; 10:524-530
4. Akaishi J, Sugino K, Kitagawa W, et al. Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid 2011; 21:1183-1189
5. Sugino K, Ito K, Mimura T, et al. The important role of operations in the management of anaplastic thyroid carcinoma. Surgery 2002; 131:245- 248
6. Kihara M, Miyauchi A, Yamauchi A, Yokomise H. Prognostic factors of anaplastic thyroid carcinoma. Surg Today 2004; 34:394-398
7. Machens A, Hinze R, Lautenschlager C, et al. Extended surgery and early postoperative radiotherapy for undifferentiated thyroid carcinoma. Thyroid 2001; 11:373-380
8. Lim SM, Shin SJ, Chung WY, et al. Treatment outcome of patients with anaplastic thyroid cancer: A single center experience. Yonsei Med J 2012; 53:352-357
9. Foote RL, Molina JR, Kasperbauer JL, et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: A single-institution experience using aggressive multimodal therapy. Thyroid 2011; 21:25-30
10. Sherman EJ, Lim SH, Ho AL, et al. Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: A critical re-evaluation including uniform pathologic review. Radiother Oncol 2011; 101:425-430
11. Nagaiah G, Hossain A, Mooney CJ, et al. Anaplastic thyroid cancer: A review of epidemiology, pathogenesis, and treatment. J Oncol 2011; 2011:542358. A good review of ATC
12. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. J Am Med Assoc 2006; 295:2164-2167
13. Ratnatunga PC, Amarasinghe SC, Ratnatunga NV. Changing patterns of thyroid cancer in Sri Lanka. Has the iodination programme helped? Ceylon Med J 2003; 48:125-128
14. Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing trends in the United States: 1999 through 2008. CA Cancer J Clin 2012 [Epub ahead of print].
15. Deshpande HA, Gettinger SN, Sosa JA. Targeted therapy for thyroid cancer: An updated review of investigational agents. Curr Opin Investig Drugs 2010; 11:661-668
16. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005; 12:245-262
17. Nagaiah G, Fu P, Wasman JK, et al. Phase II trial of sorafenib (bay 43-9006) in patients with advanced anaplastic carcinoma of the thyroid (ATC). J Clin Oncol 2009; 27:15s. (Suppl; abstr 6058).
18. Bible KC, Suman VJ, Menefee ME, et al. A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab 2012 [Epub ahead of print].
19. Horsman MR, Bohn AB, Busk M. Vascular targeting therapy: Potential benefit depends on tumor and host related effects. Exp Oncol 2010; 32:143-148
20. Hollebecque A, Massard C, Soria JC. Vascular disrupting agents: A delicate balance between efficacy and side effects. Curr Opin Oncol 2012; 24:305- 315
21. Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002; 62:3408-3416
22. Mooney CJ, Nagaiah G, Fu P, et al. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 2009; 19:233-240
23. Sosa JA, Elisei R, Jarzab B, et al. A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial. J Clin Oncol 2011; 29(Suppl):abstr 5502
24. Waller CF. Imatinib mesylate. Recent Results Cancer Res 2010; 184: 3-20
25. Ha HT, Lee JS, Urba S, et al. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid 2010; 20:975-980
26. Kawada K, Kitagawa K, Kamei S, et al. The feasibility study of docetaxel in patients with anaplastic thyroid cancer. Jpn J Clin Oncol 2010; 40:596- 599
27. Kim E, Matsuse M, Saenko V, et al. Imatinib enhances docetaxel-induced apoptosis through inhibition of nuclear factor-kB activation in anaplastic thyroid carcinoma cells. Thyroid 2012; 22:717-724
28. Gryder BE, Sodji QH, Oyelere AK. Targeted cancer therapy: Giving histone deacetylase inhibitors all they need to succeed. Future Med Chem 2012; 4:505-524
29. Thurn KT, Thomas S, Moore A, Munster PN. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol 2011; 7:263-283
30. Catalano MG, Fortunati N, Pugliese M, et al. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J Endocrinol 2006; 191:465-472
31. Noguchi H, Yamashita H, Murakami T, et al. Successful treatment of anaplastic thyroid carcinoma with a combination of oral valproic acid, chemotherapy, radiation and surgery. Endocr J 2009; 56:245-249
32. Derbel O, Limem S, Ségura-Ferlay C, et al. Results of combined treatment of anaplastic thyroid carcinoma (ATC). BMC Cancer 2011; 11:469
33. Ito K, Hanamura T, Murayama K, et al. Multimodality therapeutic outcomes in anaplastic thyroid carcinoma: Improved survival in subgroups of patients with localized primary tumors. Head Neck 2012; 34:230-237
34. Chen J, Tward JD, Shrieve DC, Hitchcock YJ. Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: Analysis of the surveillance, epidemiology, and end results 1983-2002. Am J Clin Oncol 2008; 31:460-464
35. Siironen P, Hagstrom J, MaenpaäHO, et al. Anaplastic and poorly differentiated thyroid carcinoma: Therapeutic strategies and treatment outcome of 52 consecutive patients. Oncology 2010; 79:400-408
36. Schoenfeld JD, Odejide OO, Wirth LJ, Chan AW. Survival of a patient with anaplastic thyroid cancer following intensity-modulated radiotherapy and sunitinib - a case report. Anticancer Res 2012; 32:1743-1746
37. Catalano MG, Pugliese M, Poli R, et al. Effects of the histone deacetylase inhibitor valproic acid on the sensitivity of anaplastic thyroid cancer cell lines to imatinib. Oncol Rep 2009; 21:515-521
38. Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: Phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 2000; 10:587-594.